Clinical Trial Update: Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study [Phase 3]

View source ↗

Summary

Safety evaluation update from a Phase 3 trial assessing the GSK-580299 vaccine in women from the control group in the primary study; results completed and poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Papillomavirus

Drugs mentioned

• GSK 580299 vaccine (human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2018-12-17